NASDAQ:NGM NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free NGM Stock Alerts $1.62 +0.07 (+4.52%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$1.53▼$1.6350-Day Range$1.28▼$1.9252-Week Range$0.60▼$4.69Volume3.30 million shsAverage Volume1.49 million shsMarket Capitalization$135.21 millionP/E RatioN/ADividend YieldN/APrice Target$3.68 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get NGM Biopharmaceuticals alerts: Email Address NGM Biopharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside127.4% Upside$3.68 Price TargetShort InterestHealthy3.20% of Float Sold ShortDividend StrengthN/ASustainability-0.54Upright™ Environmental ScoreNews Sentiment0.47Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.93) to ($0.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.47 out of 5 starsMedical Sector187th out of 939 stocksPharmaceutical Preparations Industry77th out of 422 stocks 3.0 Analyst's Opinion Consensus RatingNGM Biopharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.68, NGM Biopharmaceuticals has a forecasted upside of 127.4% from its current price of $1.62.Amount of Analyst CoverageNGM Biopharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.20% of the float of NGM Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNGM Biopharmaceuticals has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NGM Biopharmaceuticals has recently increased by 3.07%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNGM Biopharmaceuticals does not currently pay a dividend.Dividend GrowthNGM Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNGM Biopharmaceuticals has received a 75.70% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for NGM Biopharmaceuticals is -0.54. Previous Next 1.9 News and Social Media Coverage News SentimentNGM Biopharmaceuticals has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NGM Biopharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for NGM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added NGM Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NGM Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders35.90% of the stock of NGM Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.74% of the stock of NGM Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NGM Biopharmaceuticals are expected to grow in the coming year, from ($0.93) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NGM Biopharmaceuticals is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NGM Biopharmaceuticals is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNGM Biopharmaceuticals has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About NGM Biopharmaceuticals Stock (NASDAQ:NGM)NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.Read More NGM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NGM Stock News HeadlinesMarch 26, 2024 | americanbankingnews.comFinancial Contrast: NGM Biopharmaceuticals (NASDAQ:NGM) and AgeX Therapeutics (NYSE:AGE)March 19, 2024 | globenewswire.comNGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual MeetingMarch 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 13, 2024 | businesswire.comNGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGMMarch 12, 2024 | bizjournals.comHow a VC and a biotech founder plan to create a new biotech modelMarch 12, 2024 | msn.comOracle, Dollar General upgraded: Wall Street's top analyst callsMarch 11, 2024 | globenewswire.comNGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | msn.comTD Cowen Downgrades NGM Biopharmaceuticals (NGM)March 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… February 27, 2024 | businesswire.comNGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGMFebruary 26, 2024 | bizjournals.comThe Column Group moves forward with plan to take NGM Bio privateFebruary 26, 2024 | finanznachrichten.deNGM Biopharmaceuticals, Inc.: NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPFebruary 26, 2024 | markets.businessinsider.comNGM Bio To Be Acquired By Affiliates Of The Column Group, LPFebruary 26, 2024 | finance.yahoo.comNGM to go private through deal with investment firmFebruary 26, 2024 | marketwatch.comNGM Biopharmaceuticals Shares Drop 20% After $1.55/Shr Buyout OfferFebruary 26, 2024 | businesswire.comNGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to ShareholdersFebruary 26, 2024 | marketwatch.comNGM Biopharmaceuticals Gets Buyout Offer From Column Group AffliatesFebruary 26, 2024 | msn.comNGM Bio to go private in a $135M deal with Atlas NeonFebruary 26, 2024 | globenewswire.comNGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPFebruary 22, 2024 | finance.yahoo.comAscites Market to Observe Stunning Growth During the Study Period (2019–2032) | DelveInsightFebruary 20, 2024 | finance.yahoo.comNGM Bio to Participate in the Cowen 44th Annual Health Care ConferenceFebruary 20, 2024 | globenewswire.comNGM Bio to Participate in the Cowen 44th Annual Health Care ConferenceFebruary 13, 2024 | ca.finance.yahoo.comNGM Biopharmaceuticals, Inc. (NGM)January 19, 2024 | benzinga.comLooking Into NGM Biopharmaceuticals's Recent Short InterestJanuary 17, 2024 | finance.yahoo.comNGM Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceJanuary 9, 2024 | msn.comNGM Biopharma gains on Phase 1 data update for cancer therapyJanuary 9, 2024 | benzinga.comNGM Biopharmaceuticals Stock (NASDAQ:NGM) Dividends: History, Yield and DatesSee More Headlines Receive NGM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/27/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NGM CUSIPN/A CIK1426332 Webwww.ngmbio.com Phone(650) 243-5555FaxN/AEmployees138Year Founded1998Price Target and Rating Average Stock Price Target$3.68 High Stock Price Target$6.00 Low Stock Price Target$1.55 Potential Upside/Downside+127.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,380,000.00 Net Margins-3,223.34% Pretax Margin-3,223.34% Return on Equity-77.85% Return on Assets-67.76% Debt Debt-to-Equity RatioN/A Current Ratio7.79 Quick Ratio7.79 Sales & Book Value Annual Sales$4.42 million Price / Sales30.59 Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book0.90Miscellaneous Outstanding Shares83,460,000Free Float53,499,000Market Cap$135.21 million OptionableOptionable Beta1.26 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. William J. Rieflin J.D. (Age 64)Executive Chairman of the Board of Directors Comp: $1.1MDr. David J. Woodhouse Ph.D. (Age 53)CEO & Director Comp: $860.75kMs. Valerie L. Pierce J.D. (Age 61)Senior VP, General Counsel, Secretary & Chief Compliance Officer Comp: $580.75kDr. Hsiao Dee Lieu F.A.C.C. (Age 54)M.D., Chief Medical Officer & Executive VP Comp: $625.75kJean Frederic Viret Ph.D.Chief Financial OfficerMs. Irene PerlichVP, Corporate Controller & Principal Accounting OfficerMr. Daniel Kaplan Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsEmergent BioSolutionsNYSE:EBSCitius PharmaceuticalsNASDAQ:CTXRSyros PharmaceuticalsNASDAQ:SYRSAnnovis BioNYSE:ANVSKinnate BiopharmaNASDAQ:KNTEView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 9,472 shares on 3/11/2024Ownership: 3.349%Goldman Sachs Group Inc.Sold 162,679 shares on 3/1/2024Ownership: 0.134%GSA Capital Partners LLPBought 120,797 shares on 2/16/2024Ownership: 0.404%Vanguard Group Inc.Bought 9,472 shares on 2/15/2024Ownership: 3.350%Barclays PLCBought 52,331 shares on 2/15/2024Ownership: 0.110%View All Institutional Transactions NGM Stock Analysis - Frequently Asked Questions Should I buy or sell NGM Biopharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NGM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NGM, but not buy additional shares or sell existing shares. View NGM analyst ratings or view top-rated stocks. What is NGM Biopharmaceuticals' stock price target for 2024? 4 brokers have issued 12-month price targets for NGM Biopharmaceuticals' shares. Their NGM share price targets range from $1.55 to $6.00. On average, they expect the company's share price to reach $3.68 in the next twelve months. This suggests a possible upside of 127.4% from the stock's current price. View analysts price targets for NGM or view top-rated stocks among Wall Street analysts. How have NGM shares performed in 2024? NGM Biopharmaceuticals' stock was trading at $0.8590 at the beginning of 2024. Since then, NGM shares have increased by 88.6% and is now trading at $1.62. View the best growth stocks for 2024 here. When is NGM Biopharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NGM earnings forecast. How were NGM Biopharmaceuticals' earnings last quarter? NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.03. The company had revenue of $18.58 million for the quarter, compared to analyst estimates of $18.90 million. NGM Biopharmaceuticals had a negative trailing twelve-month return on equity of 77.85% and a negative net margin of 3,223.34%. What is David Woodhouse's approval rating as NGM Biopharmaceuticals' CEO? 3 employees have rated NGM Biopharmaceuticals Chief Executive Officer David Woodhouse on Glassdoor.com. David Woodhouse has an approval rating of 34% among the company's employees. This puts David Woodhouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. When did NGM Biopharmaceuticals IPO? NGM Biopharmaceuticals (NGM) raised $100 million in an initial public offering on Thursday, April 4th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen served as the underwriters for the IPO. Who are NGM Biopharmaceuticals' major shareholders? NGM Biopharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.35%), Vanguard Group Inc. (3.35%), Federated Hermes Inc. (0.42%), GSA Capital Partners LLP (0.40%), BNP Paribas Financial Markets (0.27%) and Bridgeway Capital Management LLC (0.24%). Insiders that own company stock include David J Woodhouse, David V Goeddel, Group L P Column, Hsiao D Lieu and Jin-Long Chen. View institutional ownership trends. How do I buy shares of NGM Biopharmaceuticals? Shares of NGM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NGM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NGM Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.